Skip to content

News

3

November 3, 2023

In Latest News, Publication and DataPosted November 3, 2023

Tallac Presents First Clinical Data for TAC-001 at SITC 2023

Categories

Latest News (9)
Publication and Data (5)

Search for:

Recent Posts

Tallac Presents First Clinical Data for TAC-001 at SITC 2023
Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting
Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors

Archives

November 2023
September 2023
January 2023
November 2022
July 2022
May 2022
October 2021
April 2021
March 2021
December 2020
November 2020

(650) 866-1966

866 Malcolm Road Suite 100, Burlingame, CA 94010

Linkedin-in Envelope

Copyright © 2020-2023 Tallac Therapeutics, Inc. All Rights Reserved.